MedTrace Logo

Microvasculature Ultrasound Super-resolution in Transplant Delayed Graft Function

NCT07645599 · Status: NOT_YET_RECRUITING · Type: OBSERVATIONAL · Enrollment: 40

Last updated 2026-06-12

No results posted yet for this study

Summary

This pilot study is testing a new ultrasound imaging method called Super-Resolution Ultrasound (SRU) to look at blood flow and tiny blood vessels in transplanted kidneys in very detailed images after kidney transplant surgery. The goal is to see whether changes in the kidney's small blood vessels can help predict how well the transplanted kidney will work early after transplant, including whether delayed graft function may occur.

Investigators hope this technique can become a safe, noninvasive way to evaluate transplanted kidneys without needing as many invasive biopsies. It may also help doctors better assess donor kidneys at higher-risk of suboptimal functioning.

Conditions

  • End Stage Chronic Renal Failure
  • Renal Transplant
  • Microvascular Changes
  • Microvascular Circulation

Interventions

DRUG

DEFINITY®

Approved drug or biologic being evaluated for a new indication, population, route of administration, or dosage level not specified in the FDA approved labeling for kidney imaging.

DIAGNOSTIC_TEST

Ultrasound contrast agent (Contrast-enhanced ultrasound)

Super-resolution ultrasound using lipid microsphere contrast

DRUG

Optison (Perflutren Protein-Type A Microspheres Injectable Suspension)

Approved drug or biologic being evaluated for a new indication, population, route of administration, or dosage level not specified in the FDA approved labeling for kidney imaging.

DRUG

Lumason® contrast agent

Approved drug or biologic being evaluated for a new indication, population, route of administration, or dosage level not specified in the FDA approved labeling for kidney imaging.

Sponsors & Collaborators

  • Roderick Tan

    lead OTHER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-06-01
Primary Completion
2028-06-30
Completion
2028-06-30
FDA Drug
Yes
FDA Device
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07645599 on ClinicalTrials.gov